Targeting Immune-Fibroblast Crosstalk in Myocardial Infarction and Cardiac Fibrosis
Inflammation and tissue fibrosis co-exist and are causally linked to organ dysfunction. However, the molecular mechanisms driving immune-fibroblast crosstalk in human cardiac disease remains unexplored and there are currently no therapeutics to target fibrosis. Here, we performed multi-omic single-cell gene expression, epitope mapping, and chromatin accessibility profiling in 38 donors, acutely infarcted, and chronically failing human hearts. We identified a disease-associated fibroblast trajectory marked by cell surface expression of fibroblast activator protein (FAP), which diverged into distinct myofibroblasts and pro-fibrotic fibroblast populations, the latter resembling matrifibrocytes. Pro-fibrotic fibroblasts were transcriptionally similar to cancer associated fibroblasts and expressed high levels of collagens and periostin (POSTN), thymocyte differentiation antigen 1 (THY-1), and endothelin receptor A (EDNRA) predicted to be driven by a RUNX1 gene regulatory network. We assessed the applicability of experimental systems to model tissue fibrosis and demonstrated that 3 different in vivo mouse models of cardiac injury were superior compared to cultured human heart and dermal fibroblasts in recapitulating the human disease phenotype. Ligand-receptor analysis and spatial transcriptomics predicted that interactions between C-C chemokine receptor type 2 (CCR2) macrophages and fibroblasts mediated by interleukin 1 beta (IL-1β) signaling drove the emergence of pro-fibrotic fibroblasts within spatially defined niches. This concept was validated through in silico transcription factor perturbation and in vivo inhibition of IL-1β signaling in fibroblasts where we observed reduced pro-fibrotic fibroblasts, preferential differentiation of fibroblasts towards myofibroblasts, and reduced cardiac fibrosis. Herein, we show a subset of macrophages signal to fibroblasts via IL-1β and rewire their gene regulatory network and differentiation trajectory towards a pro-fibrotic fibroblast phenotype. These findings highlight the broader therapeutic potential of targeting inflammation to treat tissue fibrosis and restore organ function.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
Research square - (2023) vom: 26. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Amrute, Junedh M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
C-C chemokine receptor 2 |
|---|
| Anmerkungen: |
Date Revised 23.04.2024 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.21203/rs.3.rs-2402606/v1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352578424 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352578424 | ||
| 003 | DE-627 | ||
| 005 | 20240423231914.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21203/rs.3.rs-2402606/v1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1384.xml |
| 035 | |a (DE-627)NLM352578424 | ||
| 035 | |a (NLM)36747878 | ||
| 035 | |a (PII)rs.3.rs-2402606 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Amrute, Junedh M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Targeting Immune-Fibroblast Crosstalk in Myocardial Infarction and Cardiac Fibrosis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 23.04.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Inflammation and tissue fibrosis co-exist and are causally linked to organ dysfunction. However, the molecular mechanisms driving immune-fibroblast crosstalk in human cardiac disease remains unexplored and there are currently no therapeutics to target fibrosis. Here, we performed multi-omic single-cell gene expression, epitope mapping, and chromatin accessibility profiling in 38 donors, acutely infarcted, and chronically failing human hearts. We identified a disease-associated fibroblast trajectory marked by cell surface expression of fibroblast activator protein (FAP), which diverged into distinct myofibroblasts and pro-fibrotic fibroblast populations, the latter resembling matrifibrocytes. Pro-fibrotic fibroblasts were transcriptionally similar to cancer associated fibroblasts and expressed high levels of collagens and periostin (POSTN), thymocyte differentiation antigen 1 (THY-1), and endothelin receptor A (EDNRA) predicted to be driven by a RUNX1 gene regulatory network. We assessed the applicability of experimental systems to model tissue fibrosis and demonstrated that 3 different in vivo mouse models of cardiac injury were superior compared to cultured human heart and dermal fibroblasts in recapitulating the human disease phenotype. Ligand-receptor analysis and spatial transcriptomics predicted that interactions between C-C chemokine receptor type 2 (CCR2) macrophages and fibroblasts mediated by interleukin 1 beta (IL-1β) signaling drove the emergence of pro-fibrotic fibroblasts within spatially defined niches. This concept was validated through in silico transcription factor perturbation and in vivo inhibition of IL-1β signaling in fibroblasts where we observed reduced pro-fibrotic fibroblasts, preferential differentiation of fibroblasts towards myofibroblasts, and reduced cardiac fibrosis. Herein, we show a subset of macrophages signal to fibroblasts via IL-1β and rewire their gene regulatory network and differentiation trajectory towards a pro-fibrotic fibroblast phenotype. These findings highlight the broader therapeutic potential of targeting inflammation to treat tissue fibrosis and restore organ function | ||
| 650 | 4 | |a Preprint | |
| 650 | 4 | |a C-C chemokine receptor 2 | |
| 650 | 4 | |a fibroblast activator protein | |
| 650 | 4 | |a fibrosis | |
| 650 | 4 | |a heart failure | |
| 650 | 4 | |a interleukin 1 beta | |
| 650 | 4 | |a macrophages | |
| 700 | 1 | |a Luo, Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Penna, Vinay |e verfasserin |4 aut | |
| 700 | 1 | |a Bredemeyer, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Yamawaki, Tracy |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Steven |e verfasserin |4 aut | |
| 700 | 1 | |a Kadyrov, Farid |e verfasserin |4 aut | |
| 700 | 1 | |a Heo, Gyu-Seong |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Sally Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Koenig, Andrew L |e verfasserin |4 aut | |
| 700 | 1 | |a Kuppe, Christoph |e verfasserin |4 aut | |
| 700 | 1 | |a Jones, Cameran |e verfasserin |4 aut | |
| 700 | 1 | |a Kopecky, Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a Hayat, Sikander |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Pan |e verfasserin |4 aut | |
| 700 | 1 | |a Terada, Yuriko |e verfasserin |4 aut | |
| 700 | 1 | |a Fu, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Furtado, Milena |e verfasserin |4 aut | |
| 700 | 1 | |a Kreisel, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Stitziel, Nathan O |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Chi-Ming |e verfasserin |4 aut | |
| 700 | 1 | |a Kramann, Rafael |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Yongjian |e verfasserin |4 aut | |
| 700 | 1 | |a Ason, Brandon |e verfasserin |4 aut | |
| 700 | 1 | |a Lavine, Kory J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Research square |d 2020 |g (2023) vom: 26. Jan. |w (DE-627)NLM312780982 |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:26 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21203/rs.3.rs-2402606/v1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 26 |c 01 | ||